Table 3 Cumulative incidence of MASLD for cholecystectomy and/or cardiometabolic risk factor (CMRF) ≥ 3 or < 3 (95% CI).

From: Association between cholecystectomy and the risk of new-onset metabolic dysfunction-associated steatotic liver disease: a risk-stratified cohort study

Time frame

Cumulative incidence (%) of MASLD (95% CI)

Cholecystectomy (No),

CMRF < 3

Cholecystectomy (No), CMRF ≥ 3

Cholecystectomy (Yes), CMRF < 3

Cholecystectomy (Yes), CMRF ≥ 3

1 year

0.49(0.28–0.70)

1.14(0.93–1.35)

1.02 (0.47–1.57)

4.39 (3.66–5.12)

2 years

1.39(1.32–1.74)

4.51(4.09–4.93)

1.74 (1.00–2.48)

8.18 (7.15–9.18)

3 years

2.28(1.82–2.74)

7.54(7.00–8.08)

3.23 (2.14–4.31)

11.03 (9.81–12.23)

4 years

3.06(2.52–3.6)

10.12(9.49–10.74)

4.14 (2.83–5.43)

14.43 (12.96–15.87)

5 years

3.87(3.25–4.49)

12.48(11.78–13.17)

6.29 (4.44–8.10)

17.10 (5.41–18.75)

6 years

4.78(4.07–5.49)

14.8(14.03–15.57)

6.29 (4.44–8.10) *

21.32 (19.20–23.39)

7 years

6.12(5.27–6.96)

17.28(16.46–18.13)

6.92 (4.87–8.93) *

23.48 (21.03–25.85) *

8 years

7.48(6.47–8.48)

19.05(18.12–19.98)

6.92 (4.87–8.93) *

23.48 (21.03–25.85) *

  1. Cumulative incidence was calculated by product limit (Kaplan-Meier) method of survival probability.
  2. *There was no new-onset MASLD between 72 and 96 months of survival time in Cholecystectomy (Yes), CMRF < 3 group, 84 and 96 months of survival time in Cholecystectomy (Yes), CMRF ≥ 3 group.
Back to article page